Poster Viewing Session II - Clinical
Young Investigators present their poster in a short movie and reply live to questions moderated by the session chairs.
Log in or create an account to watch this content
Subscribe now and get unlimited access to all webinars and recordings.
Now Playing: Poster Viewing Session II - Clinical
Poster Viewing Session II - Clinical
Moderators: Gilels Edan & Edgardo Cristiano
- Peripheral neuropathy as potential side effect of teriflunomide: Serena Borrelli (Brussels, Belgium)
- Sodium/potassium ratio as a conversion predictor from CIS to MS: Marlene Arbeu-Reyes (Mineral de la Reforma, Mexico)
- Quantify upper limb impairment in the ADL in people with Multiple Sclerosis: Marco Pisa (Milan, Italy)
- CONFIDENCE: Real-world effectiveness of ocrelizumab in relapsing MS over 18 months: Julius Eggebrecht (Grenzach-Wyhlen, Germany)
- Exercise therapy as supplemental treatment in early multiple sclerosis: a RCT: Morten Riemenschneider (Aarhus, Denmark)
- Humoral immune response to SARS-CoV2 vaccines in multiple sclerosis and controls: Gabriel Bsteh (Vienna, Austria)
- Prevalence of PTSD in Russian population of MS patients: Ivan Kalinin (Saint-Petersburg, Russia)
- Quality of life and fear of disease progression in MS patients with PTSD: Mariia Andreeva (Saint-Petersburg, Russia)
- Frequency of New Silent MRI lesions in MOGAD and AQP4-NMOSD: Valentina Camera (Oxford, United Kingdom)
- The impact of COVID-19 on patients with neuromyelitis optica beyond infection risk: Hexiang Yin (Beijing, China)
- Long-term disability outcomes in multiple sclerosis: a 25-year follow-up study: Sena Destan Bunul (Kocaeli, Turkey)